News
Zepbound beats Wegovy for weight loss
Digest more
People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo Nordisk’s ...
Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...
Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.
Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...
Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...
Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.
Eli Lilly launched a couple of new successful drugs, Mounjaro and Zepbound, that have boosted ... In 2021, Pfizer's COVID-19 vaccine success had many wondering how to invest in Pfizer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback